Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating initiatives including the integration and disposition of assets acquired in ...

MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.

Moderna has announced FDA approval for its new COVID-19 vaccine, mNexspike (mRNA-1283). This next-generation shot targets a ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

The biotech giant that soared during Operation Warp Speed now faces regulatory hurdles, political scepticism, and dwindling ...

A retrospective analysis of hospitalized VA patients finds that prior flu or RSV infection more than doubled the odds of ...

The company's "next-generation" COVID-19 vaccine, mNexspike, was approved for adults 65 and older and younger people at risk ...

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.

FDA approves Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk groups Phase 3 trial shows mNEXSPIKE outperforms original ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...